BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210713
DTEND;VALUE=DATE:20210716
DTSTAMP:20260515T201430
CREATED:20210302T095204Z
LAST-MODIFIED:20210302T095204Z
UID:29214-1626134400-1626393599@www.pharmajournalist.com
SUMMARY:ARDS Drug Development Summit 2021
DESCRIPTION:The inaugural ARDS Drug Development Summit will bring 60+ biopharma leaders together to discover how the rise of SARS-CoV-2 ARDS\, emergence of novel targets\, and the past 12 months of unprecedented global focus on ARDS research has transformed this graveyard of drug development failures into a starting point for the next generation of therapeutics addressing not just ARDS\, but broader\, systemic inflammation. \nVirtually uniting dedicated and experienced industry experts from Aqualung\, Bone Therapeutics\, Boehringer Ingelheim\, Athersys and more\, this trailblazing new meeting will help you overcome your most urgent drug development challenges.
URL:https://www.pharmajournalist.com/event/ards-drug-development-summit-2021/
LOCATION:Virtual
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210713
DTEND;VALUE=DATE:20210716
DTSTAMP:20260515T201430
CREATED:20210312T065852Z
LAST-MODIFIED:20210312T065852Z
UID:29308-1626134400-1626393599@www.pharmajournalist.com
SUMMARY:mRNA Based Therapeutics Summit
DESCRIPTION:The mRNA-Based Therapeutics Summit will unite the world leaders developing mRNA therapeutics to discuss learnings\, challenges and future directions concerning translation and manufacturing of your novel mRNA modality. From mRNA vaccine development for infectious disease and oncology\, effective mRNA gene therapies and novel delivery strategies\, we bring to you an all-inclusive platform dedicated to accelerating successful translation of mRNA into a transformative class of medicines.  \nTo know more about mRNA Based Therapeutics Summit please click here.
URL:https://www.pharmajournalist.com/event/mrna-based-therapeutics-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210713
DTEND;VALUE=DATE:20210716
DTSTAMP:20260515T201430
CREATED:20210312T072425Z
LAST-MODIFIED:20210312T072425Z
UID:29325-1626134400-1626393599@www.pharmajournalist.com
SUMMARY:Non-Small Cell Lung Cancer Drug Development Summit
DESCRIPTION:The Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit is the definitive industry-led forum for drug development in the largest solid tumor indication. \nThis is a strategic conference designed to bring drug development teams together to address critical challenges surrounding therapeutic potency\, tumor resistance and relapse and expanding the clinical utility of targeted and immuno-therapies\, either in combination or monotherapies. \n \nAs checkpoint inhibitors are on the brink of entering the perioperative setting and the approval of novel bispecifics with dual oncogenic targeting\, this forum will enable you to see a full picture of the clinical trial landscape and identify what MoAs and targets future biopharma investment will be put towards. \nJoin Global Innovators To: \n\nLeverage the knowledge gained from the current EGFR-TKI successes to implement it into strategies for improvement\, best application strategies and potential combination partners with AstraZeneca\, Puma Biotechnology\, Cullinan Oncology and Takeda\nUnravel the potentials of targeting currently untreatable acquired resistances through small molecules and biologics to develop novel agents against mutations with AbbVie\, Merus\, Black Diamond\, AOM Biosciences and Mirati Therapeutics\nDive into the exciting advancements in the NSCLC rare mutations space\, with the novel therapies in targeting BRAF\, NGR1 fusions and HER2 with Kinnate Biopharmaceuticals\, Elevation Oncology and Boeringer Ingelheim\nHarness the power of the immune system to treat NSCLC by delving into the current best\, novel targets and combination strategies to improve patent outlook with Merck & Co\, Immutep\, BerGenBio and Bristol-Myers Squibb\nAdvance the efficacy of companion diagnostics and look to the future of early disease detection\, application and differences in patient populations and how combination therapy can best be exploited to beat this drastically unmet clinical need with UAMS\, Takeda\, Novartis\, BloodPAC and Amgen\nA deep-dive workshop explores how to utilize EGFR-targeting in solid tumors outside of NSCLC with Maverick Therapeutics\, Black Diamond Therapeutics and Harvard Medical School\n\nNetwork with 100+ executive biopharma leaders over 3-days of comprehensive insights to uncover the latest industry knowledge on the molecular heterogeneity of lung cancer\, the implications for therapeutic design when considering acquired resistance and optimal application of new drugs in the clinic.
URL:https://www.pharmajournalist.com/event/non-small-cell-lung-cancer-drug-development-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR